Molecular targeting of angiogenesis for imaging and therapy

被引:33
作者
Brack, SS
Dinkelborg, LM
Neri, D
机构
[1] Swiss Fed Inst Technol Zurich, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, CH-8057 Zurich, Switzerland
[2] Schering AG, Res Labs, D-1000 Berlin, Germany
关键词
angiogenesis; targeting; antibody; cancer; chronic inflammation;
D O I
10.1007/s00259-004-1648-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Angiogenesis, i.e. the proliferation of new blood vessels from pre-existing ones, is an underlying process in many human diseases, including cancer, blinding ocular disorders and rheumatoid arthritis. The ability to selectively target and interfere with neovascularisation would potentially be useful in the diagnosis and treatment of angiogenesis-related diseases. This review presents the authors' views on some of the most relevant markers of angiogenesis described to date, as well as on specific ligands which have been characterised in pre-clinical animal models and/or clinical studies. Furthermore, we present an overview on technologies which are likely to have an impact on the way molecular targeting of angiogenesis is performed in the future.
引用
收藏
页码:1327 / 1341
页数:15
相关论文
共 177 条
[1]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[2]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[3]   Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream [J].
Arkin, MR ;
Wells, JA .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :301-317
[4]  
Ballara S, 2001, ARTHRITIS RHEUM, V44, P2055, DOI 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO
[5]  
2-2
[6]   Lack of specificity of endoglin expression for tumor blood vessels [J].
Balza, E ;
Castellani, P ;
Zulstra, A ;
Neri, D ;
Zardi, L ;
Siri, A .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (04) :579-585
[7]   Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen [J].
Bander, NH ;
Nanus, DM ;
Milowsky, MI ;
Kostakoglu, L ;
Vallabahajosula, S ;
Goldsmith, SJ .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :667-677
[8]   Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].
Bander, NH ;
Trabulsi, EJ ;
Kostakoglu, L ;
Yao, D ;
Vallabhajosula, S ;
Smith-Jones, P ;
Joyce, MA ;
Milowsky, M ;
Nanus, DM ;
Goldsmith, SJ .
JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721
[9]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[10]   Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results [J].
Bigner, DD ;
Brown, MT ;
Friedman, AH ;
Coleman, RE ;
Akabani, G ;
Friedman, HS ;
Thorstad, WL ;
McLendon, RE ;
Bigner, SH ;
Zhao, XG ;
Pegram, CN ;
Wikstrand, CJ ;
Herndon, JE ;
Vick, NA ;
Paleologos, N ;
Cokgor, I ;
Provenzale, JM ;
Zalutsky, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2202-2212